Symbols / CLDX Stock $31.27 +4.37% Celldex Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
CLDX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Anthony S. Marucci M.B.A.
Exch · Country NCM · United States
Market Cap 2.45B
Enterprise Value 2.00B
Income -283.65M
Sales 865.00K
FCF (ttm) -126.27M
Book/sh 6.85
Cash/sh 5.75
Employees 198
Insider 10d —
IPO May 15, 1986
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -6.95
PEG —
P/S 2,837.51
P/B 4.56
P/C —
EV/EBITDA -6.56
EV/Sales 2,317.80
Quick Ratio 8.78
Current Ratio 8.92
Debt/Eq 0.42
LT Debt/Eq —
EPS (ttm) -4.27
EPS next Y -4.50
EPS Growth —
Revenue Growth -97.80%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-07
ROA -30.89%
ROE -48.94%
ROIC —
Gross Margin 0.00%
Oper. Margin -5,629.00%
Profit Margin 0.00%
Shs Outstand 78.49M
Shs Float 72.46M
Insider Own 0.27%
Instit Own 94.89%
Short Float 10.80%
Short Ratio 10.27
Short Interest 7.14M
52W High 35.79
vs 52W High -12.63%
52W Low 19.52
vs 52W Low 60.19%
Beta 0.93
Impl. Vol. 1.56%
Rel Volume 0.64
Avg Volume 941.25K
Volume 599.81K
Target (mean) $57.53
Tgt Median $54.00
Tgt Low $38.00
Tgt High $90.00
# Analysts 15
Recom Strong_buy
Prev Close $29.96
Price $31.27
Change 4.37%
About

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$57.53
Mean price target
2. Current target
$31.27
Latest analyst target
3. DCF / Fair value
$-28.96
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$31.27
Low
$38.00
High
$90.00
Mean
$57.53

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-06-15 reit HC Wainwright & Co. Buy → Buy $42
2026-06-10 main UBS Buy → Buy $45
2026-05-13 main Wells Fargo Overweight → Overweight $54
2026-05-08 main Barclays Overweight → Overweight $48
2026-04-20 up Barclays Underweight → Overweight $45
2026-03-02 main Goldman Sachs Neutral → Neutral $34
2026-02-26 reit Stifel Buy → Buy $68
2025-12-17 main Barclays Underweight → Underweight $24
2025-11-11 main Barclays Underweight → Underweight $21
2025-10-21 init Mizuho — → Outperform $48
2025-10-13 init Barclays — → Underweight $25
2025-09-17 main Canaccord Genuity Buy → Buy $62
2025-08-20 main Wells Fargo Overweight → Overweight $38
2025-08-20 main Citigroup Buy → Buy $48
2025-08-20 main Canaccord Genuity Buy → Buy $62
2025-08-20 main HC Wainwright & Co. Buy → Buy $42
2025-06-16 reit HC Wainwright & Co. Buy → Buy $50
2025-06-13 reit HC Wainwright & Co. Buy → Buy $50
2025-05-09 main UBS Buy → Buy $38
2025-05-09 main Goldman Sachs Neutral → Neutral $31
News
RSS: Latest CLDX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-02 MARTIN SAMUEL BATES Chief Financial Officer — 4,817 $10.38 $50,000
2025-12-15 PEPIN RONALD A Officer — 19,333 $2.78 $105,714
2025-12-04 JIMENEZ FREDDY A General Counsel — 4,166 $29.10 $121,210
2025-11-13 WRIGHT RICHARD M Former — 49,298 $9.02 $692,913
2025-11-13 WRIGHT RICHARD M Former — 49,298 $24.00 $1,183,177
2025-08-13 JIMENEZ FREDDY A General Counsel — 771 $23.95 $19,096
2024-11-18 MARINO JAMES J Director — 10,500 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
1.54
-77.99%
7.02
+1.99%
6.88
+192.02%
2.36
Operating Revenue
1.54
-77.99%
7.02
+1.99%
6.88
+192.02%
2.36
Operating Expense
288.91
+42.96%
202.10
+35.70%
148.93
+36.06%
109.45
Research And Development
245.07
+49.85%
163.55
+38.59%
118.01
+43.46%
82.26
Selling General And Administration
43.84
+13.72%
38.55
+24.69%
30.91
+13.68%
27.20
General And Administrative Expense
43.84
+13.72%
38.55
+24.69%
30.91
+13.68%
27.20
Other Gand A
43.84
+13.72%
38.55
+24.69%
30.91
+13.68%
27.20
Total Expenses
288.91
+42.96%
202.10
+35.70%
148.93
+36.06%
109.45
Operating Income
-287.37
-47.31%
-195.08
-37.34%
-142.04
-32.63%
-107.10
Total Operating Income As Reported
-287.37
-47.31%
-195.08
-26.23%
-154.54
-34.11%
-115.23
EBITDA
-283.99
-47.99%
-191.90
-38.02%
-139.03
-33.43%
-104.20
Normalized EBITDA
-312.60
-36.44%
-229.12
-64.07%
-139.65
-41.10%
-98.97
Reconciled Depreciation
3.38
+6.39%
3.18
+5.62%
3.01
+3.87%
2.90
EBIT
-287.37
-47.31%
-195.08
-37.34%
-142.04
-32.63%
-107.10
Total Unusual Items
28.61
-23.12%
37.22
+5970.96%
0.61
+111.72%
-5.23
Total Unusual Items Excluding Goodwill
28.61
-23.12%
37.22
+5970.96%
0.61
+111.72%
-5.23
Special Income Charges
0.00
0.00
+100.00%
-12.50
-53.60%
-8.14
Other Special Charges
—
—
12.50
-16.67%
15.00
Impairment Of Capital Assets
—
—
0.00
0.00
Restructuring And Mergern Acquisition
—
0.00
0.00
+100.00%
-6.86
Write Off
—
—
—
—
Net Income
-258.76
-63.91%
-157.86
-11.62%
-141.43
-25.91%
-112.33
Pretax Income
-258.76
-63.91%
-157.86
-11.62%
-141.43
-25.91%
-112.33
Other Income Expense
28.61
-23.12%
37.22
+5970.96%
0.61
+111.72%
-5.23
Gain On Sale Of Security
28.61
-23.12%
37.22
+183.80%
13.11
+350.77%
2.91
Tax Provision
—
—
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-258.76
-63.91%
-157.86
-11.62%
-141.43
-25.91%
-112.33
Net Income From Continuing Operation Net Minority Interest
-258.76
-63.91%
-157.86
-11.62%
-141.43
-25.91%
-112.33
Net Income From Continuing And Discontinued Operation
-258.76
-63.91%
-157.86
-11.62%
-141.43
-25.91%
-112.33
Net Income Continuous Operations
-258.76
-63.91%
-157.86
-11.62%
-141.43
-25.91%
-112.33
Normalized Income
-287.37
-47.31%
-195.08
-37.34%
-142.04
-32.63%
-107.10
Net Income Common Stockholders
-258.76
-63.91%
-157.86
-11.62%
-141.43
-25.91%
-112.33
Diluted EPS
-3.90
-59.18%
-2.45
+16.10%
-2.92
-21.67%
-2.40
Basic EPS
-3.90
-59.18%
-2.45
+16.10%
-2.92
-21.67%
-2.40
Basic Average Shares
66.42
+3.15%
64.39
+32.91%
48.45
+3.33%
46.89
Diluted Average Shares
66.42
+3.15%
64.39
+32.91%
48.45
+3.33%
46.89
Diluted NI Availto Com Stockholders
-258.76
-63.91%
-157.86
-11.62%
-141.43
-25.91%
-112.33
Line Item Trend 2023-12-31
Total Assets
465.63
Current Assets
431.69
Cash Cash Equivalents And Short Term Investments
423.60
Cash And Cash Equivalents
34.81
Other Short Term Investments
388.78
Receivables
2.63
Accounts Receivable
2.63
Prepaid Assets
—
Other Current Assets
5.47
Total Non Current Assets
33.93
Net PPE
6.64
Gross PPE
29.02
Accumulated Depreciation
-22.39
Properties
0.00
Machinery Furniture Equipment
3.74
Construction In Progress
0.79
Other Properties
14.84
Leases
9.65
Goodwill And Other Intangible Assets
27.19
Other Intangible Assets
27.19
Non Current Prepaid Assets
0.11
Other Non Current Assets
0.11
Total Liabilities Net Minority Interest
36.46
Current Liabilities
31.12
Payables And Accrued Expenses
25.52
Payables
3.49
Accounts Payable
3.49
Current Accrued Expenses
22.03
Current Debt And Capital Lease Obligation
1.61
Current Capital Lease Obligation
1.61
Other Current Liabilities
3.99
Total Non Current Liabilities Net Minority Interest
5.33
Long Term Debt And Capital Lease Obligation
0.93
Long Term Capital Lease Obligation
0.93
Other Non Current Liabilities
4.40
Stockholders Equity
429.17
Common Stock Equity
429.17
Capital Stock
0.06
Common Stock
0.06
Preferred Stock
0.00
Share Issued
55.88
Ordinary Shares Number
55.88
Treasury Shares Number
0.00
Additional Paid In Capital
1,823.17
Retained Earnings
-1,397.36
Gains Losses Not Affecting Retained Earnings
3.31
Other Equity Adjustments
3.31
Total Equity Gross Minority Interest
429.17
Total Capitalization
429.17
Working Capital
400.57
Invested Capital
429.17
Total Debt
2.54
Capital Lease Obligations
2.54
Net Tangible Assets
401.98
Tangible Book Value
401.98
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-210.94
-33.70%
-157.78
-47.06%
-107.29
-3.43%
-103.73
Cash Flow From Continuing Operating Activities
-210.94
-33.70%
-157.78
-47.06%
-107.29
-3.43%
-103.73
Net Income From Continuing Operations
-258.76
-63.91%
-157.86
-11.62%
-141.43
-25.91%
-112.33
Depreciation Amortization Depletion
3.38
+6.39%
3.18
+5.62%
3.01
+3.87%
2.90
Depreciation
—
—
—
2.90
Depreciation And Amortization
3.38
+6.39%
3.18
+5.62%
3.01
+3.87%
2.90
Other Non Cash Items
—
—
—
-6.86
Stock Based Compensation
36.22
+5.77%
34.24
+43.33%
23.89
+53.03%
15.61
Asset Impairment Charge
—
—
0.00
0.00
Deferred Tax
—
—
0.00
0.00
Deferred Income Tax
—
—
0.00
0.00
Operating Gains Losses
0.01
-25.00%
0.02
—
0.00
Change In Working Capital
14.06
+165.08%
-21.60
-260.46%
13.46
+445.36%
-3.90
Change In Receivables
-1.31
-168.21%
1.93
+184.52%
-2.28
-1203.43%
-0.17
Change In Prepaid Assets
8.71
+143.78%
-19.89
-437.07%
5.90
+161.64%
-9.57
Change In Payables And Accrued Expense
11.03
-5.18%
11.63
+23.98%
9.38
+200.48%
3.12
Change In Other Current Assets
-3.61
+62.54%
-9.64
-321233.33%
-0.00
0.00
Change In Other Current Liabilities
-0.75
+86.64%
-5.64
-1319.91%
0.46
-83.05%
2.73
Investing Cash Flow
209.07
+172.06%
-290.13
-174.27%
-105.78
-217.61%
89.94
Cash Flow From Continuing Investing Activities
209.07
+172.06%
-290.13
-174.27%
-105.78
-217.61%
89.94
Net PPE Purchase And Sale
-2.71
-41.43%
-1.92
-5.56%
-1.82
+0.55%
-1.83
Purchase Of PPE
-2.71
-41.43%
-1.92
-5.56%
-1.82
+0.55%
-1.83
Capital Expenditure
-2.71
-41.43%
-1.92
-5.56%
-1.82
+0.55%
-1.83
Net Investment Purchase And Sale
211.79
+173.48%
-288.21
-177.22%
-103.96
-213.37%
91.70
Purchase Of Investment
-384.50
+51.32%
-789.92
-86.06%
-424.56
-124.68%
-188.97
Sale Of Investment
596.29
+18.85%
501.71
+56.49%
320.60
+14.23%
280.67
Net Other Investing Changes
—
—
—
0.07
Financing Cash Flow
2.39
-99.46%
441.45
+102.07%
218.46
+5259.62%
4.08
Cash Flow From Continuing Financing Activities
2.39
-99.46%
441.45
+102.07%
218.46
+5259.62%
4.08
Net Issuance Payments Of Debt
—
—
—
0.00
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
—
—
—
0.00
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
0.00
-100.00%
432.30
+99.93%
216.22
0.00
Proceeds From Stock Option Exercised
2.39
-73.90%
9.15
+309.26%
2.24
-45.14%
4.08
Changes In Cash
0.52
+107.97%
-6.46
-219.93%
5.38
+155.44%
-9.71
Beginning Cash Position
28.36
-18.55%
34.81
+18.30%
29.43
-24.82%
39.14
End Cash Position
28.87
+1.82%
28.36
-18.55%
34.81
+18.30%
29.43
Free Cash Flow
-213.66
-33.79%
-159.70
-46.36%
-109.11
-3.36%
-105.56
Amortization Of Securities
-5.86
+62.82%
-15.75
-153.12%
-6.22
-837.20%
0.84
Common Stock Issuance
0.00
-100.00%
432.30
+99.93%
216.22
0.00
Issuance Of Capital Stock
0.00
-100.00%
432.30
+99.93%
216.22
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category